Tazobactam Diastereomer Impurity
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

115546-66-2Tazobactam Diastereomer Impurity

● In Stock

Catalogue No.:VE0026347
CAS No.:115546-66-2
Mol. Formula:C10H12N4O5S
Mol. Weight:300.29 g/mol

Additional information on CAS 115546-66-2

Parent drug

Tazobactam

IUPAC Name

(2S,3R,5R)-3-((1H-1,2,3-Triazol-1-yl)methyl)-3-methyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide

Smiles

[H][C@@]1(C2)N([C@@H](C(O)=O)[C@](CN3C=CN=N3)(C)S1(=O)=O)C2=O

InChI

InChI=1S/C10H12N4O5S/c1-10(5-13-3-2-11-12-13)8(9(16)17)14-6(15)4-7(14)20(10,18)19/h2-3,7-8H,4-5H2,1H3,(H,16,17)/t7-,8+,10-/m1/s1

Description

Tazobactam Diastereomer Impurity (CAS 115546-66-2) is a stereochemical impurity arising from incomplete stereoselective control during tazobactam synthesis and can influence potency and stability profiles. Characterization requires chiral chromatography, HPLC, LC-MS, and 1D/2D NMR to confirm relative stereochemistry and quantify trace levels. Accurate impurity profiling supports specification setting and comparability studies consistent with ICH Q3A and ICH Q3B expectations for degradation and process-related impurities. Control strategies include optimization of asymmetric steps, recrystallization, and in-process monitoring. Technical documentation should include validated analytical methods, limits of quantitation, and batch release criteria to ensure robust quality assurance.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url